ArticleFrontiers in oncology2026
Case Report: Post-transplant lymphoproliferative disorder mimicking Baló's concentric sclerosis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-Transplant Lymphoproliferative Disorder (PTLD) is a lymphoproliferative disease that occurs in recipients of solid organ or hematopoietic stem cell transplants, resulting from the malignant transformation of benign proliferative lymphoid or plasma cell tissue due to immunosuppression. As an immunodeficiency-associated lymphoproliferative disorder, PTLD can affect various organs, including lymph nodes, the gastrointestinal tract, lungs, kidneys, and the central nervous system. The overall prognosis is generally poor. This case report describes a 37-year-old female patient presenting with magnetic resonance imaging (MRI) findings mimicking Baló's concentric sclerosis (BCS). However, pathological biopsy confirmed a diagnosis of monomorphic Primary Central Nervous System PTLD (PCNS-PTLD). The patient was treated with immunosuppression reduction combined with rituximab plus lenalidomide which led to a partial remission. Both PTLD and Baló's concentric sclerosis exhibit significant improvement with high-dose corticosteroid therapy, which can complicate the differential diagnosis. This report aims to summarize the clinical features of a case of PCNS-PTLD that mimicked Baló's concentric sclerosis to enhance the early recognition and diagnosis of PCNS-PTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.